298 related articles for article (PubMed ID: 26521469)
1. [BRAF-STATUS OF PAPILLARY THYROID CARCINOMAS AND STRATEGY OF SURGICAL TREATMENT].
Tarashchenko YN; Kovalenko AE; Bolgov MY; Guda BB; Shelkovoy EA; Nekrasov KA; Mankovskaya S; Kashuba VI
Klin Khir; 2015 Jun; (6):49-54. PubMed ID: 26521469
[TBL] [Abstract][Full Text] [Related]
2. BRAFV600E mutation in fine-needle aspiration aspirates: Association with poorer prognostic factors in larger papillary thyroid carcinomas.
Lee JI; Jang HW; Kim SW; Kim JW; Oh YL; Chung JH
Head Neck; 2013 Apr; 35(4):548-53. PubMed ID: 22488961
[TBL] [Abstract][Full Text] [Related]
3. Detection of BRAF c.1799T > A (p.V600E) mutation using residual routine fine-needle aspiration specimens of papillary thyroid carcinoma.
Zhao H; Zhang ZH; Zhou B; Xiao T; Pan QJ; Guo HQ
Diagn Cytopathol; 2015 Oct; 43(10):786-90. PubMed ID: 26152656
[TBL] [Abstract][Full Text] [Related]
4. BRAF mutation analysis of fine-needle aspiration biopsies of papillary thyroid carcinoma: impact on diagnosis and prognosis.
Colanta A; Lin O; Tafe L; Ghossein R; Nafa K; Mitchell T; Ladanyi M; Arcila M
Acta Cytol; 2011; 55(6):563-9. PubMed ID: 22156467
[TBL] [Abstract][Full Text] [Related]
5. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
[TBL] [Abstract][Full Text] [Related]
6. Study of peripheral BRAF(V600E) mutation as a possible novel marker for papillary thyroid carcinomas.
Kwak JY; Jeong JJ; Kang SW; Park S; Choi JR; Park SJ; Kim EK; Chung WY
Head Neck; 2013 Nov; 35(11):1630-3. PubMed ID: 23161556
[TBL] [Abstract][Full Text] [Related]
7. Utility of BRAF mutation detection in fine-needle aspiration biopsy samples read as "suspicious for papillary thyroid carcinoma".
Jara SM; Bhatnagar R; Guan H; Gocke CD; Ali SZ; Tufano RP
Head Neck; 2015 Dec; 37(12):1788-93. PubMed ID: 24989827
[TBL] [Abstract][Full Text] [Related]
8. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
[TBL] [Abstract][Full Text] [Related]
9. False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma.
Paek SH; Kim BS; Kang KH; Kim HS
World J Surg Oncol; 2017 Nov; 15(1):202. PubMed ID: 29132392
[TBL] [Abstract][Full Text] [Related]
10. The BRAF V600E mutation in papillary thyroid cancer with positive or suspected pre-surgical cytological finding is not associated with advanced stages or worse prognosis.
Barbaro D; Incensati RM; Materazzi G; Boni G; Grosso M; Panicucci E; Lapi P; Pasquini C; Miccoli P
Endocrine; 2014 Apr; 45(3):462-8. PubMed ID: 23925579
[TBL] [Abstract][Full Text] [Related]
11. Value of immunohistochemistry in the detection of BRAF(V600E) mutations in fine-needle aspiration biopsies of papillary thyroid carcinoma.
Zimmermann AK; Camenisch U; Rechsteiner MP; Bode-Lesniewska B; Rössle M
Cancer Cytopathol; 2014 Jan; 122(1):48-58. PubMed ID: 24039206
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays.
Ilie MI; Lassalle S; Long-Mira E; Bonnetaud C; Bordone O; Lespinet V; Lamy A; Sabourin JC; Haudebourg J; Butori C; Guevara N; Peyrottes I; Sadoul JL; Bozec A; Santini J; Capper D; von Deimling A; Emile JF; Hofman V; Hofman P
Thyroid; 2014 May; 24(5):858-66. PubMed ID: 24417277
[TBL] [Abstract][Full Text] [Related]
13. Association of BRAFV600E mutation with clinicopathological features of papillary thyroid carcinoma: a study on a Chinese population.
Liu S; Zhang B; Zhao Y; Chen P; Ji M; Hou P; Shi B
Int J Clin Exp Pathol; 2014; 7(10):6922-8. PubMed ID: 25400776
[TBL] [Abstract][Full Text] [Related]
14. BRAF mutation testing of thyroid fine-needle aspiration specimens enhances the predictability of malignancy in thyroid follicular lesions of undetermined significance.
Adeniran AJ; Hui P; Chhieng DC; Prasad ML; Schofield K; Theoharis C
Acta Cytol; 2011; 55(6):570-5. PubMed ID: 22156468
[TBL] [Abstract][Full Text] [Related]
15. Use of BRAF v600e immunocytochemistry on FNA direct smears of papillary thyroid carcinoma.
Wobker SE; Kim LT; Hackman TG; Dodd LG
Cancer Cytopathol; 2015 Sep; 123(9):531-9. PubMed ID: 26080065
[TBL] [Abstract][Full Text] [Related]
16. Allele-specific PCR with competitive probe blocking for sensitive and specific detection of BRAF V600E in thyroid fine-needle aspiration specimens.
Smith GD; Zhou L; Rowe LR; Jarboe EA; Collins BT; Bentz JS; Wittwer CT; Chadwick BE
Acta Cytol; 2011; 55(6):576-83. PubMed ID: 22156469
[TBL] [Abstract][Full Text] [Related]
17. BRAF
Bakkar S; Macerola E; Aljarrah Q; Proietti A; Materazzi G; Basolo F; Miccoli P
Updates Surg; 2019 Dec; 71(4):701-704. PubMed ID: 31586312
[TBL] [Abstract][Full Text] [Related]
18. BRAF V600E detection in cytological thyroid samples: A key component of the decision tree for surgical treatment of papillary thyroid carcinoma.
Collet JF; Lacave R; Hugonin S; Poulot V; Tassart M; Fajac A
Head Neck; 2016 Jul; 38(7):1017-21. PubMed ID: 26854757
[TBL] [Abstract][Full Text] [Related]
19. Prognostic prediction of BRAF(V600E) and its relationship with sodium iodide symporter in classic variant of papillary thyroid carcinomas.
Gao WL; Wie LL; Chao YG; Wie L; Song TL
Clin Lab; 2012; 58(9-10):919-26. PubMed ID: 23163107
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors.
Shi C; Guo Y; Lv Y; Nanding A; Shi T; Qin H; He J
PLoS One; 2016; 11(12):e0167414. PubMed ID: 27936049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
